Altus Pharmaceuticals Inc. Form SC 13G February 14, 2008

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G (Rule 13d-102)

Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No.)*

Altus Pharmaceuticals Inc. (Name of Issuer)

Common Stock (Title of Class of Securities)

02216N105 (CUSIP Number)

February 6, 2008 Date of Event Which Requires Filing of the Statement

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- o Rule 13d-1(b)
- x Rule 13d-1(c)
- o Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1 of 10

CUSIP NO.	13G	Page 2 of 10 Pages
02216N105		

1.	NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON			
	Citadel Investment Group, L.L.C.			
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) x (b) o			
3.	SEC USE ONLY			
4.	CITIZENSHIP OR PLAC Delaware limited liabilit		ΓΙΟΝ	
	NUMBER OF	5.	SOLE VOTING POWER 0	
В	SHARES ENEFICIALLY OWNED BY EACH	6.	SHARED VOTING POWER 1,663,173 shares	
	REPORTING PERSON WITH	7.	SOLE DISPOSITIVE POWER 0	
		8.	SHARED DISPOSITIVE POWER See Row 6 above.	
9.	AGGREGATE AMOUN' See Row 6 above.	Γ BENEFICIALLY	OWNED BY EACH REPORTING PERSON	
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 0			
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)			
	Approximately 5.4% ⁽¹⁾ a	as of the date of this	s filing	
12.	2. TYPE OF REPORTING PERSON OO; HC			

⁽¹⁾ Based on 30,685,108 outstanding shares of the Common Stock of Issuer, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarter ended September 30, 2007, as filed with the Securities and Exchange Commission on November 7, 2007.

CUSIP NO.	13G	Page 3 of 10 Pages
02216N105	130	1 age 3 of 10 f ages

1.	NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON			
	Citadel Limited Partner	Citadel Limited Partnership		
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) x (b) o			
3.	SEC USE ONLY			
4.	CITIZENSHIP OR PLAC Delaware limited liabilit		TION	
	NUMBER OF	5.	SOLE VOTING POWER 0	
]	SHARES BENEFICIALLY OWNED BY	6.	SHARED VOTING POWER	
	EACH REPORTING		1,663,173 shares	
	PERSON WITH	7.	SOLE DISPOSITIVE POWER 0	
	_	8.	SHARED DISPOSITIVE POWER See Row 6 above.	
9.	AGGREGATE AMOUN' See Row 6 above.	Γ BENEFICIALLY	OWNED BY EACH REPORTING PERSON	
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 0			
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)			
	Approximately 5.4% ⁽²⁾ a	as of the date of thi	s filing	
12.	TYPE OF REPORTING PERSON PN; HC			

⁽²⁾ See footnote 1 above.

	CUSIP NO. 02216N105	13G	Page 4 of 10 Pages
--	------------------------	-----	--------------------

1.	NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON		
	Kennith Griffin		
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) x (b) o		
3.	SEC USE ONLY		
4.	CITIZENSHIP OR PLAC U.S. Citizen	E OF ORGANIZA	TION
	NUMBER OF	5.	SOLE VOTING POWER 0
1	SHARES BENEFICIALLY OWNED BY	6.	SHARED VOTING POWER
	EACH REPORTING		1,663,173 shares
	PERSON WITH	7.	SOLE DISPOSITIVE POWER 0
		8.	SHARED DISPOSITIVE POWER See Row 6 above.
9.	AGGREGATE AMOUN' See Row 6 above.	Γ BENEFICIALLY	OWNED BY EACH REPORTING PERSON
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 0		
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)		
	Approximately 5.4% ⁽³⁾ a	s of the date of thi	s filing
12.	TYPE OF REPORTING PERSON IN; HC		

⁽³⁾ See footnote 1 above.

CUSIP NO. 02216N105	13G	Page 5 of 10 Pages
------------------------	-----	--------------------

1.	NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON			
	Citadel Equity Fund Ltd.			
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) x (b) o			
3.	SEC USE ONLY			
4.	CITIZENSHIP OR PLAC Cayman Islands compar		TION	
	NUMBER OF	5.	SOLE VOTING POWER 0	
]	SHARES BENEFICIALLY OWNED BY	6.	SHARED VOTING POWER	
	EACH REPORTING		1,663,173 shares	
	PERSON WITH	7.	SOLE DISPOSITIVE POWER 0	
		8.	SHARED DISPOSITIVE POWER See Row 6 above.	
9.	AGGREGATE AMOUN' See Row 6 above.	Γ BENEFICIALLY	OWNED BY EACH REPORTING PERSON	
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 0			
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)			
	Approximately 5.4% ⁽⁴⁾ a	s of the date of thi	s filing	
12.	TYPE OF REPORTING PERSON CO			

⁽⁴⁾ See footnote 1 above.

CUSIP NO.	120	Daga 6 of 10 Dagas
02216N105	13G	Page 6 of 10 Pages

Item 1(a) Name of Issuer: **Altus Pharmaceuticals Inc.**

1(b) Address of Issuer's Principal Executive Offices:

125 Sidney Street Cambridge, Massachusetts 02139

Item 2(a)Name of Person Filing(5)Item 2(b)Address of Principal Business OfficeItem 2(c)Citizenship

Citadel Investment Group, L.L.C. 131 S. Dearborn Street 32nd Floor Chicago, Illinois 60603 Delaware limited liability company

Citadel Limited Partnership 131 S. Dearborn Street 32nd Floor Chicago, Illinois 60603 Delaware limited partnership

Kenneth Griffin 131 S. Dearborn Street 32nd Floor Chicago, Illinois 60603 U.S. Citizen

Citadel Equity Fund Ltd. c/o Citadel Investment Group, L.L.C. 131 S. Dearborn Street 32nd Floor Chicago, Illinois 60603 C a y m a n I s l a n d s company

(5) Citadel Holdings Ltd., a Cayman Islands company ("CH"), is majority owned by Citadel Kensington Global Strategies Fund Ltd., a Bermuda company ("CKGSF"). Citadel Equity Fund Ltd. ("CEF") is a subsidiary of CH. CKGSF and CH do not have control over the voting or disposition of securities held by CEF.

Edgar Filing: Altus Pharmaceuticals Inc. - Form SC 13G

CUSIP NO. 02216N105	13G	Page 7 of 10 Pages
2(d) Title of Class of Securities:		
	Common Stock,	par value \$0.01
2(e) CUSIP Number: (02216N105	
Item 3 If this statement	is filed pursuant to Rules 13d-1(b), o	or 13d-2(b) or (c), check whether the person filing is a:
(a)	[] Broker or dealer regi	stered under Section 15 of the Exchange Act;
(b)	[] Bank as defin	ned in Section 3(a)(6) of the Exchange Act;
(c) [_] Insurance company as de	efined in Section 3(a)(19) of the Exchange Act;

Page 7 of 10

CUSIP NO. 02216N105	13G	Page 8 of 10 Pages	
(d) [_]	Investment company registered	under Section 8 of the Invest	ment Company Act;
(e) An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);			
(f) [_] A	(f) [_] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);		
(g) [_] A	A parent holding company or control	person in accordance with R	ule 13d-1(b)(1)(ii)(G);
(h) []	A savings association as defined in S	Section 3(b) of the Federal D	eposit Insurance Act;
(i) [] A church plan to Investment Con	that is excluded from the definition npany Act;	of an investment company	under Section 3(c)(14) of the
(j)	[] Group, i	n accordance with Rule 13d-	1(b)(1)(ii)(J).
If this statement is filed	pursuant to Rule 13d-1(c), check thi	s box. x	
Item 4	Ow	nership:	
CITADEL INVESTM CITADEL LIMITED KENNETH GRIFFIN CITADEL EQUITY F	PARTNERSHIP		
	(a)	Amount beneficially owned	:
1,663,173 shares			
(b) Percent of Class:			
Approximately 5.4% ⁽⁶⁾	as of the date of this filing		
(Number of s	hares as to which such perso	n has:
	(i) sole por	wer to vote or to direct the vo	ote:
		()
Page 8 of 10			

CUSIP NO. 02216N105	13G	Page 9 of 10 Pages			
(ii) shared power to vote or to direct the vote:		rote:			
See Item 4(a) above.	See Item 4(a) above.				
(iii	sole power to di	spose or to direct the disposi	tion of:		
		()		
(iv)	shared power to d	ispose or to direct the dispos	sition of:		
See Item 4(a) above.					
Item 5	Ownership of Five Pe	rcent or Less of a Class:			
Not Applicable.					
Item 6	Ownership of More than Five Pe	rcent on Behalf of Another P	Person:		
Not Applicable.					
I t e mIdentification an 7 Parent Holding C	nd Classification of the Subsidiary Company:	which Acquired the Securit	ty Being Reported on by the		
See Item 2 above.					
Item 8	Identification and Classifica	tion of Members of the Grou	ıp:		
Not Applicable.					
Item 9	Notice of Diss	olution of Group:			
Not Applicable.					
(6)	See footno	te 1 above.			
Item 10	Cert	tification:			

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

^{*} John C. Nagel is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission on February 24, 2006, and hereby incorporated by reference

Edgar Filing: Altus Pharmaceuticals Inc. - Form SC 13G

herein. The power of attorney was filed as an attachment to a filing by Citadel Limited Partnership on Schedule 13G for Morgans Hotel Group Co.

Page 9 of 10

Edgar Filing: Altus Pharmaceuticals Inc. - Form SC 13G

CUSIP NO.	13G	Page 10 of 10 Pages
02216N105		

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated this 14th day of February, 2008.

KENNETH GRIFFIN	CITADEL EQUITY FUND LTD.
By: <u>/s/ John C. Nagel</u>	By: Citadel Limited Partnership,
John C. Nagel, attorney-in-fact*	its Portfolio Manager
CITADEL LIMITED PARTNERSHIP	By: Citadel Investment Group, L.L.C., its General Partner
By: Citadel Investment Group, L.L.C.,	
its General Partner	By: /s/ John C. Nagel
By: <u>/s/ John C. Nagel</u>	John C. Nagel, Authorized Signatory
John C. Nagel, Authorized Signatory	CITADEL INVESTMENT GROUP, L.L.C.
	By: <u>/s/ John C. Nagel</u> John C. Nagel, Authorized Signatory

Page 10 of 10